Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
626 Leser
Artikel bewerten:
(2)

EGF Theramed Health Corp: EGF Theramed Signs Agreement to Acquire Seedadelic Med Corp.

VANCOUVER, BC / ACCESSWIRE / December 14, 2020 / EGF Theramed Health Corp. (CSE:TMED)(OTCQB:EVAHF)(FSE:AUHP) (the "Company") is pleased to announce that the Company has entered into a letter of intent dated as of December 14, 2020 to acquire all of the issued and outstanding shares of Seedadelic Med Corp. ("Seedadelic"), a private Ontario corporation) in exchange for the issuance of 15,000,000 common shares of the Company at a deemed price of $0.115 per common share to Seedadelic shareholders (the "Proposed Transaction"). The Company has also agreed to pay a finder's fee on the closing of the Proposed Transaction.)

The Proposed Transaction will provide the Company with ownership of Seedadelic, a seedbank holding consisting of LSA and psychedelic properties. LSA is a legal alternative to LSD consisting of similar properties and effects of D-lysergic acid diethylamide but with less side effects. Seedbank will allow the Company to market and commercialize in a legal and rapid pace.

"We are incredibly pleased to be on the forefront of psychedelic technology. LSA is an underutilized and very rarely recognized compared to its alternative LSD. We feel there is a significant gap in the market that we can fill with LSA products and its properties," stated Jatinder Dhaliwal - Chief Executive Officer of the Company.

Readers are cautioned that the final terms and structure for the Proposed Transaction have not yet been determined. Completion of the Proposed Transaction remains subject to the negotiation of definitive documentation, completion of customary due diligence and receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied. The Company will provide additional information regarding the Proposed Transaction as soon as it becomes available.

FOR MORE INFORMATION PLEASE CONTACT:
EGF THERAMED HEALTH CORP.

Doug McFaul
Email: dmcfaul@emprisecapital.com
Telephone: (778) 331-8505

Disclaimer and Forward-Looking Statements
This news release may include forward-looking statements that are subject to inherent risks and uncertainties. All statements within this news release, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those described in forward-looking statements. Factors that could cause actual results to differ materially from those described in forward-looking statements include fluctuations in market prices, including metal prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under applicable laws.

SOURCE: EGF Theramed Health Corp



View source version on accesswire.com:
https://www.accesswire.com/620857/EGF-Theramed-Signs-Agreement-to-Acquire-Seedadelic-Med-Corp

© 2020 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.